The Health Research Institute of Santiago de Compostela (IDIS) is a biomedical research centre focusing on translational investigation. For 15 years, it has worked as a synergy among University Hospital of Santiago de Compostela (CHUS) from the Galician Health System (SERGAS) and the University of Santiago de Compostela (USC), promoting and enhancing excellence in research, scientifical and technological knowledge and its further translation to product, and teaching. Its ultimate objective is to improve population’s health. Nowadays over 1200 professionals are grouped in more than 100 research groups belonging to 7 areas: Oncology; Genetics and Systems’ Biology; Endocrinology, Nutrition and Metabolism; Neurosciences; Platforms and Methodologies; Cardiovascular; and Infectiology, Inflammation and Vaccines.
The Musculoskeletal Pathology Group started its research path in 2016. We are focused on the research and treatment of the different pathologies that affect the musculoskeletal system, such as osteoarthritis, osteoporosis, rheumatoid arthritis, and heterotopic ossification, always maintaining the patient-oriented research. The group comprises researchers from all the areas related to musculoskeletal pathologies: Pharmacy, Biology, Biotechnology, Physiotherapy, Rheumatology, Orthopaedics, and Rehabilitation. The PI of the group, Dr Rodolfo Gómez, has published more than a hundred scientific articles, many of them in journals of high impact and international relevance such as “Nature Reviews Rheumatology”, “Annals of the Rheumatic Diseases”, and “Arthritis and Rheumatology”.
The Musculoskeletal Pathology Group has obtained over 20 research projects, resulting in the raise of more than €2 million in these years. These allowed the group to stablish several research lines and national and international collaborations with other research groups.
Within the ENDOTARGET project, IDIS-SERGAS is the project leader of the Work Package 3: “Proof of Concept Studies-Systemic and local mechanisms driving intra-articular systemic endotoxemia and joint destruction”. Concretely, here we will utilize LPS or bacteria derived products isolated from the microbiota of rheumatic patients and study their inflammatory effects in joint cells and animal models. Our main strengths in this project are our expertise on Toll-like receptors (TLRs), drug discovery for rheumatic pathologies, and power proteomic analysis. For this project we will offer a list of drugs or functional foods able to decrease the pro-inflammatory responses associated to the systemic endotoxemia. Moreover, we will be able to offer a list of up-regulated and down-regulated serum proteins associated to the onset and progression of the studied rheumatic pathologies.
With this work we want to make our contribution to improve the health and quality of life of the rheumatic diseases’ patients, increasing their knowledge about their conditions and therapeutic options.
For further information see: